EcoDrugPlus

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSPSNG00000005702
Gene Symbol: GRIN2B
3 Cross references
330 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSPSNG00000021017
Gene Symbol: GRIN2C
1 Cross references
244 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2d

Ensembl ID : ENSPSNG00000018957
Gene Symbol: GRIN2D
3 Cross references
278 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSPSNG00000007905
Gene Symbol: GRIN3A
3 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSPSNG00000008329
Gene Symbol: GRIN3B
1 Cross references
286 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSPSNG00000016547
Gene Symbol: GRIK1
3 Cross references
302 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSPSNG00000015353
Gene Symbol: GRIK2
3 Cross references
331 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSPSNG00000017499
Gene Symbol: GRIK3
3 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSPSNG00000020143
Gene Symbol: GRIK4
3 Cross references
260 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPSNG00000014767
Gene Symbol: GRIK5
3 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSPSNG00000007653
Gene Symbol: GRM2
3 Cross references
276 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSPSNG00000017034
Gene Symbol: GRM3
3 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).